Progression-free survival as a surrogate for overall survival in trials of immune checkpoint inhibitors in pan cancer evaluated by RECIST 1.1

被引：0
|
作者：
Lin, L. [1 ]
Xu, H. [1 ]
Ding, J. [1 ]
Qin, T. [1 ]
Xu, M. [1 ]
Shen, J. [1 ]
Jiang, W. [1 ]
Wang, J. [1 ]
Cheng, D. [1 ]
Li, Z. [1 ]
Hu, H. [1 ]
Yu, Y. [1 ]
Yao, H. [1 ]
机构：
[1] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Dept Med Oncol,Phase Clin Trial Ctr 1, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1016/j.annonc.2020.10.523
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
36P
引用
收藏
页码：S1430 / S1430
页数：1
相关论文
共 50 条
  • [1] Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors
    Memmott, Regan M.
    Wolfe, Adam R.
    Carbone, David P.
    Williams, Terence M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (07) : 1086 - 1098
  • [2] Progression-free survival as a surrogate for overall survival in advanced cancer.
    Gillies, Eric
    Holdai, Veera
    Cowall, David Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] PROGRESSION-FREE SURVIVAL AS A SURROGATE FOR OVERALL SURVIVAL IN METASTATIC BREAST CANCER
    Beauchemin, C.
    Cooper, D.
    Lapierre, M. E.
    Yelle, L.
    Lachaine, J.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A414 - A414
  • [4] PROGRESSION-FREE SURVIVAL AS A SURROGATE FOR OVERALL SURVIVAL IN METASTATIC BREAST CANCER
    Beauchemin, C.
    Cooper, D.
    Lapierre, M.
    Yelle, L.
    Lachaine, J.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 119 - 120
  • [5] Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review
    Belin, Lisa
    Tan, Aidan
    De Rycke, Yann
    Dechartres, Agnes
    [J]. BRITISH JOURNAL OF CANCER, 2020, 122 (11) : 1707 - 1714
  • [6] Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review
    Lisa Belin
    Aidan Tan
    Yann De Rycke
    Agnès Dechartres
    [J]. British Journal of Cancer, 2020, 122 : 1707 - 1714
  • [7] Rethinking Progression-Free Survival (PFS) as a Clinical Trials Surrogate for Overall Survival (OS)
    Stewart, D.
    Bosse, D.
    Ocana, A.
    Goss, G.
    Jonker, D.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1782 - S1782
  • [8] Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
    Beauchemin, Catherine
    Cooper, Dan
    Lapierre, Marie-Eve
    Yelle, Louise
    Lachaine, Jean
    [J]. ONCOTARGETS AND THERAPY, 2014, 7 : 1101 - 1110
  • [9] Progression-free survival (PFS) as a surrogate for overall survival (OS)
    Stewart, David J.
    Bosse, Dominick
    Hilton, John
    Goss, Glenwood
    Fung-Kee-Fung, Michael
    Jonker, Derek
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [10] Validation of progression-free survival (PFS) as surrogate endpoint in randomised trials of immune checkpoint inhibitors in advanced solid cancers
    Kok, P. S.
    Yoon, W-H.
    Marschner, I.
    Lord, S. J.
    Friedlander, M.
    Lee, C. K.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 520 - 520
12345